Literature DB >> 25682557

Intra- and inter-observer agreement on diagnosis of Dupuytren disease, measurements of severity of contracture, and disease extent.

Dieuwke C Broekstra1, Rosanne Lanting2, Paul M N Werker3, Edwin R van den Heuvel4.   

Abstract

INTRODUCTION: Dupuytren disease (DD) is a fibrosing disease affecting the palmar aponeurosis, and is mostly treated by surgery based on measurement of severity of flexion contracture of the fingers. Literature concerning the measurement reliability is scarce. This study aimed to determine the intra- and inter-observer agreement of four variables for diagnosing DD, determining severity of contracture, and disease extent. One of them is a new measurement on the area of nodules and cords for measuring the disease extent in early disease stages.
METHODS: An agreement study (n = 54) was performed by two trained investigators. Agreement was calculated per finger, based on an intraclass correlation coefficient (ICC) using a latent variable model on subjects for diagnosis and Tubiana stage. For total passive extension deficit (TPED) and the area of nodules and cords, agreement was calculated with an ICC using a one-way random effects model with subject as random effect.
RESULTS: Inter-observer agreement was very good for diagnosing DD (ICC: 95.5%-99.9%) and good to very good for classifying Tubiana stage (ICC: 73.5%-94.9%). Agreements for area and TPED were moderate (middle finger) to very good (ICC: 48.4%-98.6% and 45.0%-99.5%, respectively). Intra-observer agreement was slightly higher on average than inter-observer agreement.
CONCLUSION: Overall, the intra- and inter-observer agreement in diagnosing DD, and determining the severity of flexion contracture is high. Also, the newly introduced variable area of nodules and cords has high intra- and inter-observer agreement, indicating that it is suitable to measure disease extent.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Articular; Dupuytren contracture; Observer variation; Range of motion; Reproducibility of results

Mesh:

Year:  2015        PMID: 25682557     DOI: 10.1016/j.math.2015.01.010

Source DB:  PubMed          Journal:  Man Ther        ISSN: 1356-689X


  4 in total

1.  Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.

Authors:  Jagdeep Nanchahal; Catherine Ball; Ines Rombach; Lynn Williams; Nicola Kenealy; Helen Dakin; Heather O'Connor; Dominique Davidson; Paul Werker; Susan J Dutton; Marc Feldmann; Sarah E Lamb
Journal:  Lancet Rheumatol       Date:  2022-04-29

2.  Visual Estimation of Dupuytren's Flexion Contractures-A Prospective Comparative Trial.

Authors:  Joseph P Corkum; Joshua A Gillis; David T Tang
Journal:  Plast Surg (Oakv)       Date:  2018-01-09       Impact factor: 0.947

3.  Measurement properties of the Dutch Unité Rhumatologique des Affections de la Main and its ability to measure change due to Dupuytren's disease progression compared with the Michigan Hand outcomes Questionnaire.

Authors:  Dieuwke C Broekstra; Edwin R van den Heuvel; Rosanne Lanting; Paul M N Werker
Journal:  J Hand Surg Eur Vol       Date:  2018-02-13

4.  Examiners' influence on the measured active and passive extension deficit in finger joints affected by Dupuytren disease.

Authors:  Jesper Nordenskjöld; Stina Brodén; Isam Atroshi
Journal:  BMC Med Res Methodol       Date:  2018-10-29       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.